Trinity Biotech Secures Over 2M Orders for HIV Rapid Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 16 2026
0mins
Trinity Biotech announced that it has received additional purchase orders for over 2M units of its rapid HIV test, TrinScreen HIV. These orders are scheduled for fulfillment in Q3 and are expected to make a meaningful contribution to the company's 2026 revenue and profitability objectives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRIB
About TRIB
Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trinity Biotech Launches CGM+ Monitoring Technology
- Clinical Data Validation: Trinity Biotech's CGM+ platform successfully identifies nocturnal compression-related false low glucose events through over 5,000 hours of clinical wear data, showcasing its differentiation potential in the $15 billion global CGM market.
- Technological Advantage: By integrating multi-sensor technology with AI-driven analytics, CGM+ provides richer physiological data than traditional CGM systems, significantly enhancing user experience and reducing disruptions caused by false alarms.
- Market Opportunity: Management believes that CGM+'s multi-sensor architecture not only addresses user pain points in diabetes management but also offers more accurate data for automated insulin delivery systems, thereby enhancing commercial opportunities and partner relevance.
- Future Development: CGM+ is entering the later stages of pivotal trials and regulatory submissions, with plans to further integrate nocturnal compression low detection capabilities to meet market demand for more effective diabetes management solutions.
See More
Trinovium Secures Silver Membership in OCP, Enhancing AI Data Center Solutions
- Market Potential: The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, with a CAGR of 31.5%, providing Trinovium with significant opportunities for product development.
- OCP Membership: Trinovium's Silver Membership in the Open Compute Project allows it to engage directly in the standardization of global data center infrastructure, enhancing the company's influence in the liquid cooling sector.
- Innovation Acceleration: Collaborating with OCP will expedite the development and validation of Trinovium's cooling technologies, ensuring compliance with evolving hyperscale computing demands, thereby strengthening its competitive edge.
- Strategic Positioning: Leveraging Trinity Biotech's expertise in high-purity fluid science and analytical technologies, Trinovium aims to meet the increasing performance and reliability requirements of AI data centers, further solidifying its position in the emerging market.
See More
Trinity Biotech Terminates Standby Equity Purchase Agreement
- Financing Strategy Shift: Trinity Biotech plc has formally notified YA II PN, LTD. of the termination of its Standby Equity Purchase Agreement (SEPA), indicating that the company does not intend to utilize this equity line of credit facility, reflecting a strategic shift in its financing approach.
- Market Impact Assessment: This move may affect the company's future liquidity and market confidence, particularly as it seeks to achieve profitable operations and market acceptance of new products, potentially exerting negative pressure on its stock price.
- Forward-Looking Statement Risks: The company highlighted various risks in its announcement regarding forward-looking statements, including the impact of COVID-19, potential disruptions in government funding, and product market acceptance, all of which could influence its future growth potential.
- Business Expansion Plans: Trinity Biotech's recent acquisition of biosensor assets from Waveform Technologies marks its entry into the wearable biosensor industry, showcasing its diversified development strategy in the diagnostics market, although the termination of the financing agreement may exert pressure on its expansion plans.
See More
Trinity Launches AI Data Center Cooling Subsidiary Trinovium
- Trinity's New Subsidiary: Trinity launched Trinovium, focusing on liquid cooling solutions for AI data centers, leveraging existing manufacturing capabilities without substantial capital investment, thereby enhancing operational efficiency and seizing rapid market growth opportunities.
- Stock Price Surge: Trinity's stock rose over 16% following the subsidiary launch, indicating strong investor confidence in the company's new strategy, with retail sentiment shifting from 'bearish' to 'extremely bullish'.
- Quanterix Leadership Change: Quanterix's newly appointed CFO Jason Faessler officially took office, aiming to bring stability to the company; however, despite progress in Alzheimer's testing, the stock has declined about 50% over the past year.
- Recon's Technical Rebound: Recon's stock rebounded over 27% in after-hours trading after hitting a record low of $0.43, reflecting speculative buying and short position closures, despite an 83% decline over the past year due to capital-raising pressures.
See More
Trinity Biotech Launches New Subsidiary Trinovium for AI Cooling Solutions
- Market Potential: The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, with a CAGR of 31.5%, highlighting the strong demand for liquid-cooled infrastructure driven by increasing AI compute density.
- Technology Integration: Trinovium will leverage Trinity's expertise in ultra-high-purity fluid manufacturing and analytical technologies to address reliability challenges in next-generation liquid cooling systems, thereby enhancing the company's competitive position in the rapidly evolving AI infrastructure market.
- Capital Efficiency: By reallocating existing manufacturing capacity in the U.S. and EU, Trinovium can enter the liquid cooling market in a capital-efficient manner, which is expected to provide additional operational leverage and profit growth potential for the company.
- Innovative Product Development: Trinovium has developed an initial formulation for direct-to-chip liquid cooling that meets Open Compute Project standards, aimed at enhancing system reliability and performance to meet the high demands of AI infrastructure for cooling fluids.
See More
Trinity Biotech Reports Q1 2026 Earnings with Revenue Growth
- Significant Loss Reduction: Trinity Biotech reported a net loss of $4.39 million for Q1 2026, translating to a loss of $0.23 per share, which is a 50% decrease from last year's loss of $8.79 million or $0.48 per share, indicating progress in cost management.
- Strong Revenue Growth: Total revenue for the first quarter reached $10.85 million, a 43% increase year-over-year, primarily driven by a surge in sales of Rapid HIV tests, which rose from $0.4 million last year to $3.7 million, reflecting a significant uptick in market demand.
- Improved EBITDA: The EBITDA loss for this quarter was $1.95 million, considerably lower than the $5.84 million loss reported last year, while adjusted EBITDA showed a loss of $1.06 million, demonstrating enhanced operational efficiency.
- Positive Future Outlook: The company anticipates completing over 2 million orders for its TrinScreen HIV tests in Q3 2026 and plans to scale up UniGold HIV commercially during the same quarter, aiming to improve gross margins and cash flow as part of its Comprehensive Transformation Plan.
See More
Trinity Biotech Launches CGM+ Monitoring Technology
- Clinical Data Validation: Trinity Biotech's CGM+ platform successfully identifies nocturnal compression-related false low glucose events through over 5,000 hours of clinical wear data, showcasing its differentiation potential in the $15 billion global CGM market.
- Technological Advantage: By integrating multi-sensor technology with AI-driven analytics, CGM+ provides richer physiological data than traditional CGM systems, significantly enhancing user experience and reducing disruptions caused by false alarms.
- Market Opportunity: Management believes that CGM+'s multi-sensor architecture not only addresses user pain points in diabetes management but also offers more accurate data for automated insulin delivery systems, thereby enhancing commercial opportunities and partner relevance.
- Future Development: CGM+ is entering the later stages of pivotal trials and regulatory submissions, with plans to further integrate nocturnal compression low detection capabilities to meet market demand for more effective diabetes management solutions.
See More
Trinovium Secures Silver Membership in OCP, Enhancing AI Data Center Solutions
- Market Potential: The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, with a CAGR of 31.5%, providing Trinovium with significant opportunities for product development.
- OCP Membership: Trinovium's Silver Membership in the Open Compute Project allows it to engage directly in the standardization of global data center infrastructure, enhancing the company's influence in the liquid cooling sector.
- Innovation Acceleration: Collaborating with OCP will expedite the development and validation of Trinovium's cooling technologies, ensuring compliance with evolving hyperscale computing demands, thereby strengthening its competitive edge.
- Strategic Positioning: Leveraging Trinity Biotech's expertise in high-purity fluid science and analytical technologies, Trinovium aims to meet the increasing performance and reliability requirements of AI data centers, further solidifying its position in the emerging market.
See More
Trinity Biotech Terminates Standby Equity Purchase Agreement
- Financing Strategy Shift: Trinity Biotech plc has formally notified YA II PN, LTD. of the termination of its Standby Equity Purchase Agreement (SEPA), indicating that the company does not intend to utilize this equity line of credit facility, reflecting a strategic shift in its financing approach.
- Market Impact Assessment: This move may affect the company's future liquidity and market confidence, particularly as it seeks to achieve profitable operations and market acceptance of new products, potentially exerting negative pressure on its stock price.
- Forward-Looking Statement Risks: The company highlighted various risks in its announcement regarding forward-looking statements, including the impact of COVID-19, potential disruptions in government funding, and product market acceptance, all of which could influence its future growth potential.
- Business Expansion Plans: Trinity Biotech's recent acquisition of biosensor assets from Waveform Technologies marks its entry into the wearable biosensor industry, showcasing its diversified development strategy in the diagnostics market, although the termination of the financing agreement may exert pressure on its expansion plans.
See More
Trinity Launches AI Data Center Cooling Subsidiary Trinovium
- Trinity's New Subsidiary: Trinity launched Trinovium, focusing on liquid cooling solutions for AI data centers, leveraging existing manufacturing capabilities without substantial capital investment, thereby enhancing operational efficiency and seizing rapid market growth opportunities.
- Stock Price Surge: Trinity's stock rose over 16% following the subsidiary launch, indicating strong investor confidence in the company's new strategy, with retail sentiment shifting from 'bearish' to 'extremely bullish'.
- Quanterix Leadership Change: Quanterix's newly appointed CFO Jason Faessler officially took office, aiming to bring stability to the company; however, despite progress in Alzheimer's testing, the stock has declined about 50% over the past year.
- Recon's Technical Rebound: Recon's stock rebounded over 27% in after-hours trading after hitting a record low of $0.43, reflecting speculative buying and short position closures, despite an 83% decline over the past year due to capital-raising pressures.
See More
Trinity Biotech Launches New Subsidiary Trinovium for AI Cooling Solutions
- Market Potential: The data center liquid cooling market is projected to grow from $4 billion in 2026 to $27 billion by 2033, with a CAGR of 31.5%, highlighting the strong demand for liquid-cooled infrastructure driven by increasing AI compute density.
- Technology Integration: Trinovium will leverage Trinity's expertise in ultra-high-purity fluid manufacturing and analytical technologies to address reliability challenges in next-generation liquid cooling systems, thereby enhancing the company's competitive position in the rapidly evolving AI infrastructure market.
- Capital Efficiency: By reallocating existing manufacturing capacity in the U.S. and EU, Trinovium can enter the liquid cooling market in a capital-efficient manner, which is expected to provide additional operational leverage and profit growth potential for the company.
- Innovative Product Development: Trinovium has developed an initial formulation for direct-to-chip liquid cooling that meets Open Compute Project standards, aimed at enhancing system reliability and performance to meet the high demands of AI infrastructure for cooling fluids.
See More
Trinity Biotech Reports Q1 2026 Earnings with Revenue Growth
- Significant Loss Reduction: Trinity Biotech reported a net loss of $4.39 million for Q1 2026, translating to a loss of $0.23 per share, which is a 50% decrease from last year's loss of $8.79 million or $0.48 per share, indicating progress in cost management.
- Strong Revenue Growth: Total revenue for the first quarter reached $10.85 million, a 43% increase year-over-year, primarily driven by a surge in sales of Rapid HIV tests, which rose from $0.4 million last year to $3.7 million, reflecting a significant uptick in market demand.
- Improved EBITDA: The EBITDA loss for this quarter was $1.95 million, considerably lower than the $5.84 million loss reported last year, while adjusted EBITDA showed a loss of $1.06 million, demonstrating enhanced operational efficiency.
- Positive Future Outlook: The company anticipates completing over 2 million orders for its TrinScreen HIV tests in Q3 2026 and plans to scale up UniGold HIV commercially during the same quarter, aiming to improve gross margins and cash flow as part of its Comprehensive Transformation Plan.
See More
